Japan T-cell Therapy Market Size & Outlook, 2021-2028
Japan t-cell therapy market, 2018-2028 (US$M)
Related Markets
Japan t-cell therapy market highlights
- The Japan t-cell therapy market generated a revenue of USD 456.5 million in 2021 and is expected to reach USD 1,608.1 million by 2028.
- The Japan market is expected to grow at a CAGR of 19.7% from 2022 to 2028.
- In terms of segment, commercialized was the largest revenue generating modality type in 2021.
- Commercialized is the most lucrative modality type segment registering the fastest growth during the forecast period.
T-cell therapy market data book summary
| Market revenue in 2021 | USD 456.5 million |
| Market revenue in 2028 | USD 1,608.1 million |
| Growth rate | 19.7% (CAGR from 2021 to 2028) |
| Largest segment | Commercialized |
| Fastest growing segment | Commercialized |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2028 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Commercialized |
| Key market players worldwide | Novartis AG ADR, Merck KGaA, Gilead Sciences Inc, Adaptimmune Therapeutics PLC ADR, Bluebird bio Inc, Sorrento Therapeutics Inc, Fate Therapeutics Inc, Pfizer Inc, Amgen Inc, Bristol-Myers Squibb Co |
Other key industry trends
- In terms of revenue, Japan accounted for 7.2% of the global t-cell therapy market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2028.
- In Asia Pacific, China t-cell therapy market is projected to lead the regional market in terms of revenue in 2028.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 4,671.3 million by 2028.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
T-cell Therapy Market Scope
T-cell Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan t-cell therapy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to t-cell therapy market will help companies and investors design strategic landscapes.
Commercialized was the largest segment with a revenue share of 100% in 2021. Horizon Databook has segmented the Japan t-cell therapy market based on commercialized covering the revenue growth of each sub-segment from 2018 to 2028.
In May 2019, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Kymriah, making it the first T-cell therapy to be approved in Japan. The price of the drug in Japan is similar to that in the U.S. at USD 373,000. As the main competitor for the drug Yescarta is yet to be approved in the country, Novartis is estimated to highly benefit from the early approval.
Kymriah is expected to be listed for reimbursement in the near future, leading to an increase in its adoption. The MHLW approved the drug post data reviews from T-cell clinical trials ELIANA and JULIET, including investigational studies from Japan.
Reasons to subscribe to Japan t-cell therapy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Japan t-cell therapy market databook
-
Our clientele includes a mix of t-cell therapy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan t-cell therapy market , including forecasts for subscribers. This country databook contains high-level insights into Japan t-cell therapy market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Partial client list
Japan t cell therapy market size, by modality type, 2018-2028 (US$M)
Japan T-cell Therapy Market Outlook Share, 2021 & 2028 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
